138 related articles for article (PubMed ID: 8349779)
1. Ramoplanin susceptibility testing criteria.
Barry AL; Pfaller MA; Fuchs PC
J Clin Microbiol; 1993 Jul; 31(7):1932-5. PubMed ID: 8349779
[TBL] [Abstract][Full Text] [Related]
2. Comparison of agar dilution, tube dilution, and broth microdilution susceptibility tests for determination of ramoplanin MICs.
Kenny MT; Brackman MA
J Clin Microbiol; 1994 May; 32(5):1364-5. PubMed ID: 8051270
[TBL] [Abstract][Full Text] [Related]
3. Effect of protein on ramoplanin broth microdilution minimum inhibitory concentrations.
Scotti R; Dulworth JK; Kenny MT; Goldstein BP
Diagn Microbiol Infect Dis; 1993 Oct; 17(3):209-11. PubMed ID: 8112029
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms.
Collins LA; Eliopoulos GM; Wennersten CB; Ferraro MJ; Moellering RC
Antimicrob Agents Chemother; 1993 Jun; 37(6):1364-6. PubMed ID: 8328787
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of ramoplanin (A16686 or MDL62198). A new depsipeptide complex for potential topical use.
Jones RN; Barry AL
Diagn Microbiol Infect Dis; 1989; 12(3):279-82. PubMed ID: 2507218
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci.
Lawrence T; Rotstein C; Beam TR; Gorzynski EA; Amsterdam D
Antimicrob Agents Chemother; 1993 Apr; 37(4):896-900. PubMed ID: 8494388
[TBL] [Abstract][Full Text] [Related]
7. Ramoplanin versus methicillin-resistant Staphylococcus aureus: in vitro experience.
Brumfitt W; Maple PA; Hamilton-Miller JM
Drugs Exp Clin Res; 1990; 16(8):377-83. PubMed ID: 2097143
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.
Shonekan D; Mildvan D; Handwerger S
Antimicrob Agents Chemother; 1992 Jul; 36(7):1570-2. PubMed ID: 1324649
[TBL] [Abstract][Full Text] [Related]
9. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.
Bartoloni A; Colao MG; Orsi A; Dei R; Giganti E; Parenti F
J Antimicrob Chemother; 1990 Nov; 26(5):627-33. PubMed ID: 1688341
[TBL] [Abstract][Full Text] [Related]
10. Levofloxacin disk potency and tentative interpretive criteria for susceptibility tests.
Pfaller MA; Barry AL; Fuchs PC
J Clin Microbiol; 1993 Jul; 31(7):1924-6. PubMed ID: 8349777
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
Citron DM; Merriam CV; Tyrrell KL; Warren YA; Fernandez H; Goldstein EJ
Antimicrob Agents Chemother; 2003 Jul; 47(7):2334-8. PubMed ID: 12821492
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of RP 59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin-resistant Enterococcus faecium.
Ristow TA; Noskin GA; Warren JR; Peterson LR
Microb Drug Resist; 1995; 1(4):335-9. PubMed ID: 9158806
[TBL] [Abstract][Full Text] [Related]
13. Spectrum and antimicrobial activity of alexomycin (PNU-82, 127), a peptide compound projected for use in animal health.
Marshall SA; Jones RN
Diagn Microbiol Infect Dis; 1999 Mar; 33(3):181-6. PubMed ID: 10092967
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of ramoplanin on staphylococci.
Francis J; Webster H; Newsom SW
Drugs Exp Clin Res; 1990; 16(9):457-60. PubMed ID: 2100247
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial activity of ceftobiprole against gram-negative and gram-positive pathogens: results from INVITA-A-CEFTO Brazilian study.
Cereda RF; Azevedo HD; Girardello R; Xavier DE; Gales AC;
Braz J Infect Dis; 2011; 15(4):339-48. PubMed ID: 21861004
[TBL] [Abstract][Full Text] [Related]
16. Bactericidal activity of ramoplanin against antibiotic-resistant enterococci.
Johnson CC; Taylor S; Pitsakis P; May P; Levison ME
Antimicrob Agents Chemother; 1992 Oct; 36(10):2342-5. PubMed ID: 1444316
[TBL] [Abstract][Full Text] [Related]
17. In-vitro activity of ramoplanin (a novel lipoglycopeptide), vancomycin, and teicoplanin against gram-positive clinical isolates from cancer patients.
Rolston KV; Dholakia N; Ho DH; LeBlanc B; Dvorak T; Streeter H
J Antimicrob Chemother; 1996 Aug; 38(2):265-9. PubMed ID: 8877541
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
Kanj SS; Whitelaw A; Dowzicky MJ
Int J Antimicrob Agents; 2014 Feb; 43(2):170-8. PubMed ID: 24315313
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of 43 antimicrobial agents tested against ampicillin-resistant enterococci and gram-positive species resistant to vancomycin.
Yamane N; Jones RN
Diagn Microbiol Infect Dis; 1991; 14(4):337-45. PubMed ID: 1889183
[TBL] [Abstract][Full Text] [Related]
20. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1995). I. Susceptibility distribution].
Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Takanashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Kosakai N; Yamaguchi K; Matsumoto T; Kashitani F; Tanaka M
Jpn J Antibiot; 1997 Mar; 50(3):219-50. PubMed ID: 9575353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
